期刊
LANCET
卷 400, 期 10360, 页码 1345-1362出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(22)01200-4
关键词
-
资金
- European-Latin American ESCALON consortium - EU [825510]
- National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre
Hepatocellular carcinoma is a common cancer worldwide, with non-alcoholic fatty liver disease becoming a dominant cause. Treatment options are varied, including surgery, radiation, and medication. With the approval of new drugs and the development of immunotherapy, the outlook for hepatocellular carcinoma patients has improved, but the optimal sequencing of drugs and predictive biomarkers still need further research.
Hepatocellular carcinoma is one of the most common cancers worldwide and represents a major global health-care challenge. Although viral hepatitis and alcohol remain important risk factors, non-alcoholic fatty liver disease is rapidly becoming a dominant cause of hepatocellular carcinoma. A broad range of treatment options are available for patients with hepatocellular carcinoma, including liver transplantation, surgical resection, percutaneous ablation, and radiation, as well as transarterial and systemic therapies. As such, clinical decision making requires a multidisciplinary team that longitudinally adapts the individual treatment strategy according to the patient's tumour stage, liver function, and performance status. With the approval of new first-line agents and second-line agents, as well as the establishment of immune checkpoint inhibitor-based therapies as standard of care, the treatment landscape of advanced hepatocellular carcinoma is more diversified than ever. Consequently, the outlook for patients with hepatocellular carcinoma has improved. However, the optimal sequencing of drugs remains to be defined, and predictive biomarkers are urgently needed to inform treatment selection. In this Seminar, we present an update on the causes, diagnosis, molecular classification, and treatment of hepatocellular carcinoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据